The complement system is a network of roughly 50 proteins circulating in your blood and embedded in cell membranes, working as a rapid-response arm of your immune system that can identify, tag, and destroy threats within seconds of encountering them. Unlike the adaptive immune system, which takes days to build tailored antibodies against a new invader, complement is always on patrol, ready to punch holes in bacteria, recruit reinforcements, and flag debris for cleanup. What makes complement fascinating, and occasionally dangerous, is that the same destructive machinery pointed at pathogens can turn against your own tissues when regulation breaks down, a feature that links it to diseases ranging from kidney failure to age-related blindness.
Three Ways to Light the Fuse
Complement can be switched on through three separate triggering mechanisms, each responding to different signals but all funneling into the same downstream cascade. The classical pathway fires when a large protein complex called C1 recognizes antibodies that have latched onto a pathogen or a clump of cellular debris. C1 is itself a multi-part assembly: a recognition piece (C1q) plus a pair of enzyme subunits, collectively weighing in at about 774 kilodaltons. Once C1q detects the characteristic molecular patterns on antibody-coated targets, the enzymes activate and the cascade begins.1PubMed Central. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade
The lectin pathway works similarly but skips the antibody step entirely. Instead, recognition molecules like mannose-binding lectin latch directly onto sugar patterns found on the surfaces of bacteria, fungi, and viruses. When mannose-binding lectin docks onto these sugar arrays, it triggers its own set of enzymes that feed into the same cascade the classical pathway uses.2PubMed Central. The mannose-binding lectin: a prototypic pattern recognition molecule This pathway is especially important in the early days of an infection, before your adaptive immune system has had time to produce antibodies.
The alternative pathway is the most ancient and, in some ways, the strangest of the three. It runs all the time. A small fraction of the complement protein C3 spontaneously breaks down in the blood through a process sometimes called “tick-over,” generating a molecule that can bind another protein, Factor B, to form an enzyme complex capable of cutting even more C3. The result is a low-level patrol that amplifies rapidly when it encounters a surface that lacks the protective markers your own cells carry.3PubMed Central. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb) Studies modeling this process quantitatively have confirmed that once C3b lands on a pathogen’s surface, it triggers a powerful amplification loop that rapidly coats the invader.4PLoS ONE. Quantitative Modeling of the Alternative Pathway of the Complement System Researchers continue to debate the exact balance between spontaneous hydrolysis in fluid and contact-driven activation on surfaces, but the net effect is the same: a hair-trigger defense that does not need antibodies to get started.5PubMed. Initiation of the alternative pathway of complement and the history of tickover
What Complement Actually Does to a Pathogen
All three pathways converge on the same set of effector weapons. The most dramatic is the membrane attack complex, or MAC. Late-stage complement proteins (C5b through C9) assemble into a ring-shaped pore that punctures the outer membrane of a target cell. Water and ions rush in, the cell swells, and it bursts. This is the literal “lysis” arm of complement, and it is particularly effective against certain gram-negative bacteria whose thin outer walls are vulnerable to pore formation.6PubMed Central. Complement Membrane Attack Complex: New Roles, Mechanisms of Action, and Therapeutic Targets
But punching holes is not the only trick. When C3 is cleaved, one of the fragments (C3b) coats the pathogen’s surface like a molecular “eat me” sign. Immune cells such as macrophages carry receptors that recognize C3b and its breakdown products, allowing them to grab and engulf the tagged target. In the liver, specialized macrophages called Kupffer cells rely on a receptor called CRIg that binds C3b and a related fragment (iC3b) to snag complement-coated bacteria straight out of the bloodstream.7Cell. CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens This tagging process, called opsonization, is often more important than direct killing, because many pathogens are tough enough to resist pore formation but not tough enough to escape a macrophage that has grabbed onto their complement coat.
The Inflammatory Signal Flares
Every time complement chews through C3 or C5, it also releases small protein fragments called anaphylatoxins. C3a and C5a are the main ones, and despite being tiny (around 10 kilodaltons each), they punch far above their weight as inflammatory signals. They attract white blood cells toward the site of infection, activate mast cells to release histamine, and ramp up the permeability of blood vessels so that more immune cells and fluid can flood into the tissue.8PubMed. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses C5a is the more potent of the two. Its effector functions include drawing in neutrophils and macrophages and pushing them into a more aggressive, kill-ready state.9PubMed Central. The role of the anaphylatoxins in health and disease
This signaling role matters beyond infection. In sepsis, for instance, the complement cascade can go into overdrive, flooding the body with C5a. Rather than helping, the overload paralyzes the very immune cells it was supposed to activate, contributing to what researchers call “immune paralysis” and multi-organ failure.10PubMed. The role of complement, C5a and its receptors in sepsis and multiorgan dysfunction syndrome The same molecule that saves your life during a small cut can become part of the problem during a system-wide crisis.
How Your Own Cells Avoid Friendly Fire
Given that complement is always active at a low level and can amplify explosively, your own cells need constant protection. This protection comes in two layers: regulators floating free in the blood, and regulators anchored directly to your cell membranes.
In the blood, the single most important regulator of the alternative pathway is Factor H. This large soluble protein patrols the fluid phase and also docks onto your own cell surfaces, where it accelerates the breakdown of C3b before it can assemble into a functioning enzyme complex. Factor H essentially tells complement “this surface is friendly, stand down.”11PubMed Central. Complement control protein factor H: the good, the bad, and the inadequate The C-terminal end of Factor H is critical for recognizing host cells and binding to their surfaces, although its fluid-phase regulatory function can proceed even when that end is blocked.12PubMed Central. The C-terminus of complement factor H is essential for host cell protection
On cell surfaces, several membrane-bound regulators provide a second line of defense. CD46, CD55, and CD59 are the best known. CD55 speeds the disassembly of complement enzyme complexes that have already formed on the cell, while CD59 intercepts the MAC during its final assembly step, preventing the pore-forming protein C9 from inserting and polymerizing into a complete ring.13Nature Communications. Structural basis for membrane attack complex inhibition by CD59 Mouse studies in which both CD55 and CD59 were knocked out showed that the two regulators work together: losing both led to severe complement-driven kidney injury that was far worse than losing either one alone.14The Journal of Immunology. Critical Protection from Renal Ischemia Reperfusion Injury by CD55 and CD59 The takeaway is that healthy cells do not simply ignore complement; they actively suppress it at multiple checkpoints.
Complement in the Brain
One of the most surprising discoveries about complement has nothing to do with infection. During brain development, the same complement proteins used to tag pathogens for destruction also tag synapses, the connections between neurons, for removal. C1q, C3, and C4 deposit on weaker or less-active synaptic connections, marking them for engulfment by microglia, the brain’s resident immune cells. This pruning process is essential for wiring a functional brain: without it, the circuits that let you see, hear, and learn remain noisy and imprecise.15PubMed. The complement system: an unexpected role in synaptic pruning during development and disease
Microglia exist in a highly active, phagocytic state during the developmental window when synaptic pruning peaks, and complement tags serve as a key signal telling them which synapses to consume.16PubMed. Complement System in Neural Synapse Elimination in Development and Disease The concern is that the same mechanism can reactivate in the adult brain. In neurodegenerative conditions, complement components reappear at synapses and may drive inappropriate elimination, contributing to the synapse loss seen in diseases like Alzheimer’s and glaucoma.17PubMed Central. The Role of Complement in Synaptic Pruning and Neurodegeneration Researchers are now investigating whether blocking complement at the synapse could slow neurodegeneration without crippling immune defense elsewhere in the body.
How Pathogens Fight Back
If complement were invincible, infections would be rare. In reality, a large number of successful human pathogens have evolved specific countermeasures. One of the most common strategies is hijacking the host’s own Factor H. By coating themselves with Factor H stolen from the blood, bacteria essentially disguise their surfaces as “self,” shutting down the alternative pathway amplification loop that would otherwise destroy them.18PubMed Central. Factor H Family Proteins in Complement Evasion of Microorganisms
Research has shown that many of these microbes bind Factor H at the same spot, a region on domain 20 of the protein that overlaps with the site Factor H uses to dock onto your own cells. Some microbial proteins go further, forming a three-way complex with Factor H and C3b that actively suppresses complement activity right on the pathogen’s surface.19PLoS Pathogens. Microbes Bind Complement Inhibitor Factor H via a Common Site This shared strategy across unrelated species suggests that complement exerts enormous evolutionary pressure: any pathogen that cannot deal with it tends not to survive long enough to cause disease.
When Complement Drives Disease
Too little complement is a problem, and so is too much. Deficiency of early classical pathway proteins, especially C1q, is one of the strongest known genetic risk factors for developing systemic lupus erythematosus (SLE). About 93% of individuals with complete C1q deficiency develop lupus-like disease, and C4 deficiency carries roughly a 75% risk.20PubMed Central. Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway The leading explanation is that without complement to clear dying cells and immune complexes, debris accumulates, triggers autoantibody production, and fuels chronic inflammation.
On the other side, overactive or poorly regulated complement chews through the body’s own tissues. Two kidney diseases illustrate this clearly: atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy. Both are linked to genetic abnormalities in alternative pathway control, particularly in Factor H and a cluster of related genes. In aHUS, uncontrolled complement activation destroys the small blood vessels in the kidneys, while in C3 glomerulopathy, excessive complement deposits accumulate in the kidney’s filtration units.21PubMed. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome Different patterns of gene variation within the same gene cluster steer the disease toward one condition or the other.22PubMed Central. CFHR Gene Variations Provide Insights in the Pathogenesis of the Kidney Diseases Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy
The eye is another vulnerable target. Age-related macular degeneration, the most common cause of vision loss in older adults, has a well-established genetic link to Factor H. People carrying certain variants in the CFH gene have lower Factor H levels and higher levels of alternative pathway activation products in their blood, leaving the delicate structures at the back of the eye exposed to complement-mediated damage.23Human Molecular Genetics. Systemic complement levels in patients with age-related macular degeneration carrying rare or low-frequency variants in the CFH gene
Complement-Targeting Drugs
The realization that complement drives so many diseases has made it a prime drug target. The first major success was eculizumab, a monoclonal antibody that blocks C5, the protein whose cleavage generates both the inflammatory signal C5a and the starting piece of the membrane attack complex. Eculizumab was originally developed for paroxysmal nocturnal hemoglobinuria (PNH), a rare condition in which red blood cells lack the surface regulators (particularly CD55 and CD59) that normally protect them from complement. Without those shields, complement destroys red blood cells around the clock, causing severe anemia, fatigue, blood clots, and dark-colored urine.24PubMed. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria Blocking C5 with eculizumab rapidly and sustainably reduced the destruction of red blood cells, cut transfusion requirements, and improved anemia and fatigue.25PubMed Central. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria
Since eculizumab’s approval, the field has expanded. Newer C5 inhibitors with longer dosing intervals are now available, and drugs targeting C3, Factor B, and Factor D are in various stages of development for conditions ranging from C3 glomerulopathy to geographic atrophy (the advanced dry form of macular degeneration). One trade-off with all complement-blocking therapies is infection risk: because you are partially disarming the immune system’s first responder, patients on these drugs face increased vulnerability to bacteria that complement normally kills, particularly meningococcus. Vaccination against meningococcal disease is standard before starting treatment.
Complement’s Role in Transplantation
Organ transplantation creates a situation where complement activation is almost inevitable. The moment blood flow is restored to a transplanted organ, a process called ischemia-reperfusion injury triggers all three complement pathways. The ischemic period (when the organ has no blood supply) primes complement, and reperfusion (when blood flow returns) unleashes it. The resulting cascade generates anaphylatoxins and membrane attack complexes that damage the graft’s blood vessels and surrounding tissue.26PubMed. Research progress on the complement system in ischemia-reperfusion injury of organ transplantation This complement-driven injury affects not only immediate graft function but also longer-term survival, especially for kidneys and hearts.27PubMed Central. Immune response associated with ischemia and reperfusion injury during organ transplantation
For kidney transplants specifically, complement also plays a role in antibody-mediated rejection, where the recipient’s antibodies coat the donor organ and trigger the classical pathway. On top of that, patients whose original kidney disease was caused by complement dysregulation (such as aHUS or C3 glomerulopathy) face high rates of disease recurrence in the new organ, since the genetic defect in complement regulation persists.28Nephrology Dialysis Transplantation. Complement activation in kidney transplantation Complement inhibitors are increasingly being explored as a way to protect transplanted organs during and after surgery.
Connections to Clotting and Cancer
Complement does not operate in a vacuum. It shares regulatory proteins with the blood clotting cascade, and the two systems activate each other in ways researchers are still mapping. Thrombin, the key enzyme in clot formation, can directly cleave complement components, while complement activation products promote clot formation. This cross-talk helps explain why diseases with heavy complement involvement, such as PNH and aHUS, carry a high risk of dangerous blood clots.29PubMed Central. Complement-Coagulation Cross-Talk: A Potential Mediator of the Physiological Activation of Complement by Low pH The shared regulators and mutual amplification loops between the two systems mean that calming one often helps calm the other.30PubMed Central. Interactions between coagulation and complement–their role in inflammation
In cancer, complement’s role is more conflicted. You might expect it to help kill tumor cells, and in some laboratory settings it does. But within the real tumor microenvironment, complement activation appears to tip the balance toward promoting tumor growth rather than suppressing it. Chronic, low-grade complement activation in and around tumors can fuel inflammation that supports cancer cell survival, suppress anti-tumor immune responses, and encourage new blood vessel formation that feeds the growing mass.31PubMed Central. The role of complement in tumor growth Meanwhile, many tumor cells upregulate the same membrane-bound complement regulators (CD46, CD55, CD59) that healthy cells use, shielding themselves from MAC-mediated killing.32Central European Journal of Immunology. The expression of membranous complement inhibitors CD46, CD55 and CD59 in the primary and metastatic colon cancer cell lines derived from the same patient Understanding these dual roles is one of the active frontiers in cancer immunology.
Complement Inside Cells and in Adaptive Immunity
For decades, complement was considered a strictly extracellular system: proteins floating in the blood doing their work outside cells. That picture has shifted. Research now shows that some complement components, particularly C3 and its fragments, operate inside immune cells. In human T cells, intracellular cleavage of C3 and the resulting activation of the surface receptor CD46 drive the metabolic shifts that push resting T cells toward becoming active, inflammatory helper cells.33Immunity. Intracellular Complement Activation Sustains T Cell Homeostasis and Mediates Effector Differentiation This means complement is not just an innate defense system that works before the adaptive immune system kicks in; it is woven into the machinery of adaptive immunity itself, influencing how T cells decide what kind of response to mount.
An Ancient System with Deep Roots
Complement predates the adaptive immune system by hundreds of millions of years. The central protein C3 likely started as an intracellular defense molecule in single-celled organisms, protecting individual cells from microbial invaders. As multicellular life evolved, C3 gained a secretory function, allowing it to patrol the spaces between cells. Once animals developed circulatory systems, the liver became the factory producing large quantities of C3 and related proteins, flooding the bloodstream with complement.34PubMed Central. Evolution of the complement system: from defense of the single cell to guardian of the intravascular space
The lectin pathway, which uses sugar-binding molecules rather than antibodies, is thought to be the oldest activation route. A lectin-based complement system consisting of a recognition molecule and C3 has been found in ascidians, the sea squirts that are our closest invertebrate relatives. Researchers have isolated lectins and associated enzymes from a range of invertebrates and lower vertebrates, supporting the view that complement was already protecting animals long before jawed vertebrates evolved the antibody-based immune system we tend to think of first.35PubMed. The lectin-complement pathway–its role in innate immunity and evolution